WOCKPHARMA Wockhardt Ltd Earnings Reports Announcement 2025 - Financial Results Wockhardt Ltd reported audited financial results for FY25 showing a 5% revenue increase to INR 3,033 Cr and EBITDA growth of 67% to INR 418 Cr. The company also filed for approval of its antibiotic Zaynich in India in March 2025, with plans for a US filing by August 2025..Find Corporate Announcements for Press Releases, AGM, Insider Trading & SAST, Results and Corporate Action for Wockhardt Ltd